LIVIVO - Search results -

Search results

Result 1 - 10 of total 274

Article: Vivre avec une MICI.

Hébuterne, Xavier

2019 Volume 68, Issue 2, Page(s) 183–184

Title translation	Living with an IBD.
MeSH term(s)	Humans ; Inflammatory Bowel Diseases
Language	French
Publishing date	2019-02-05
Publishing country	France
Document type	Journal Article
ZDB-ID	205365-2
ISSN	2101-017X ; 0035-2640
ISSN (online)	2101-017X
ISSN	0035-2640
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.433: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article: Nutrition anti-inflammatoire et MICI : que dire à nos patients ?

Hébuterne, Xavier

Société francophone nutrition clinique et métabolisme (SFNCM) Nutrition clinique et métabolisme. 2019 June, v. 33, no. 2

2019

Abstract: A diet rich in fruits and vegetables, fish, and lower in meat and sweets is associated with a lower risk of developing IBD. There is no “anti-inflammatory diet” whose effectiveness is demonstrated. These regimens can be expensive, they cause deficiencies, ...

Abstract	A diet rich in fruits and vegetables, fish, and lower in meat and sweets is associated with a lower risk of developing IBD. There is no “anti-inflammatory diet” whose effectiveness is demonstrated. These regimens can be expensive, they cause deficiencies, and they reduce the pleasure of eating and are desocializing. During IBD, prolonged intake of oral supplements is not recommended: it is usually ineffective and possibly dangerous. Doctors must promote a pleasure diet, healthy, varied, balanced and adapted to the symptoms of the disease. Accompaniment by a dietician is recommended.
Keywords	diet ; fish ; meat ; risk
Language	English
Dates of publication	2019-06
Size	p. 126-130.
Publishing place	Elsevier Masson SAS
Document type	Article
Note	NAL-AP-2-clean
ZDB-ID	1131758-9
ISSN	0985-0562
ISSN	0985-0562
DOI	10.1016/j.nupar.2019.02.003
Database	NAL-Catalogue (AGRICOLA)

In stock of ZB MED Cologne/Königswinter

Zs.A 3512: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Moyens diagnostiques des maladies inflammatoires chroniques de l'intestin.

Hébuterne, Xavier

La Revue du praticien

2014 Volume 64, Issue 9, Page(s) 1216–1221

Abstract: The diagnosis of inflammatory bowel disease (IBD) is based on the association of clinical, biological, radiological, endoscopic, and histological parameters. This article focuses on the different diagnostic and prognostic tools used in IBD. ...

Title translation	Diagnostic tools of inflammatory bowel diseases.
Abstract	The diagnosis of inflammatory bowel disease (IBD) is based on the association of clinical, biological, radiological, endoscopic, and histological parameters. This article focuses on the different diagnostic and prognostic tools used in IBD.
MeSH term(s)	Chronic Disease ; Colitis, Ulcerative/diagnosis ; Crohn Disease/diagnosis ; Cytodiagnosis/methods ; Diagnostic Imaging/methods ; Diagnostic Techniques, Digestive System ; Humans ; Inflammatory Bowel Diseases/diagnosis ; Severity of Illness Index
Language	French
Publishing date	2014-11
Publishing country	France
Document type	English Abstract ; Journal Article ; Review
ZDB-ID	205365-2
ISSN	2101-017X ; 0035-2640
ISSN (online)	2101-017X
ISSN	0035-2640
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.433: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Nutrition et cancer : pourquoi intervenir avant 5 % de perte de poids ?

Hébuterne, Xavier

Nutrition clinique et métabolisme. 2015 May, v. 29, no. 2

2015

Abstract: The prevalence of malnutrition is high in cancer and is on average around 40%. These data are obtained with the usual criteria that refer in particular to a weight loss of 10% or more. However, if we consider that a patient with a 5% weight loss is ... ...

Abstract	The prevalence of malnutrition is high in cancer and is on average around 40%. These data are obtained with the usual criteria that refer in particular to a weight loss of 10% or more. However, if we consider that a patient with a 5% weight loss is already at nutritional risk, the prevalence of protein-energy malnutrition is above 55%. Finally, only 15% of cancer patients have not lost any weight. The analysis of medical literature suggests that in medical oncology, a weight loss of 5% is associated with an alteration of the patient's prognosis (increased morbidity and mortality). Many studies show that, during radiotherapy and chemo-radiotherapy, dietetic counselling, associated or not with the use of oral nutritional supplements, can improve the prognosis of patients. During chemotherapy, data are less convincing but most studies have proposed insufficient support in already malnourished patients and more studies are needed. During radio-chemotherapy for cancers of the upper aerodigestive tract, prophylactic placement of a gastrostomy, before any nutritional intervention, is associated with a better prognosis for the patient and is recommended. In surgery, the nutritional preoperative load is recommended in malnourished and non-malnourished patients before major surgery and early postoperative oral or enteral nutrition is associated with a reduction in infectious complications and mortality.
Keywords	diet counseling ; dietary supplements ; drug therapy ; enteral feeding ; morbidity ; mortality ; neoplasms ; nutrition risk assessment ; nutritional intervention ; patients ; prognosis ; protein energy malnutrition ; radiotherapy ; surgery ; weight loss
Language	English
Dates of publication	2015-05
Size	p. 126-131.
Publishing place	Elsevier SAS
Document type	Article
ZDB-ID	1131758-9
ISSN	0985-0562
ISSN	0985-0562
DOI	10.1016/j.nupar.2015.02.001
Database	NAL-Catalogue (AGRICOLA)

In stock of ZB MED Cologne/Königswinter

Zs.A 3512: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The management of emergency hospital visits for inflammatory bowel diseases: A French national expert consensus report.

Hébuterne, Xavier / Peyrin-Biroulet, Laurent / Hausfater, Pierre

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

2019 Volume 52, Issue 4, Page(s) 420–426

Abstract: Background: Management of inflammatory bowel diseases (IBD) in the emergency department is often suboptimal.: Aims: To develop a national consensus checklist of indicators to facilitate decision-making in emergency departments concerning ... ...

Abstract	Background: Management of inflammatory bowel diseases (IBD) in the emergency department is often suboptimal. Aims: To develop a national consensus checklist of indicators to facilitate decision-making in emergency departments concerning hospitalisation and referral for abdominopelvic computed tomography (CT). Methods: A Delphi survey was used to obtain consensus on a checklist of clinical and biological variables. 119 healthcare professionals experienced in treating IBD were invited to participate. Panellists were provided with a literature survey and invited to agree or disagree with items on a prototype checklist. Two successive rounds of voting were organised. Results: The prototype checklist included fifteen clinical or laboratory indicators for hospitalisation or CT. Four indicators were not retained in the Delphi process and four additional indicators added. The final indicators retained were: abdominal signs/symptoms of disease exacerbation, intravenous morphine titration, fever, vomiting, dehydration, recent intestinal surgery, ano-perineal abscess, bowel obstruction, haemodynamic instability, anaemia, acute kidney failure and elevated C-reactive protein. Consensus for the retained indicators was >88%. Conclusions: Use of this consensus checklist for the management of IBD in the emergency department may help improve standards of care and thus reduce the burden of these diseases.
MeSH term(s)	Checklist ; Clinical Decision-Making ; Consensus ; Delphi Technique ; Emergency Service, Hospital/standards ; France ; Health Care Surveys ; Hospitalization ; Humans ; Inflammatory Bowel Diseases/diagnosis ; Inflammatory Bowel Diseases/therapy ; Quality Indicators, Health Care ; Referral and Consultation ; Tomography, X-Ray Computed
Language	English
Publishing date	2019-11-14
Publishing country	Netherlands
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	1459373-7
ISSN	1878-3562 ; 1125-8055
ISSN (online)	1878-3562
ISSN	1125-8055
DOI	10.1016/j.dld.2019.10.015
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1134: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Effectiveness of golimumab intensification in ulcerative colitis: A multicentric prospective study.

Fumery, Mathurin / Nancey, Stéphane / Filippi, Jérôme / Altwegg, Romain / Hébuterne, Xavier / Boshetti, Gilles / Barraud, Mathilde / Meynier, Jonathan / Paul, Stéphane / Roblin, Xavier

Alimentary pharmacology & therapeutics

2023 Volume 57, Issue 11, Page(s) 1290–1298

Abstract: Introduction: Loss of response to golimumab occurs in nearly 40% of patients with ulcerative colitis (UC). Unlike others anti-TNF, no study has reported a correlation between serum golimumab level and response to drug intensification. The objective of ... ...

Abstract	Introduction: Loss of response to golimumab occurs in nearly 40% of patients with ulcerative colitis (UC). Unlike others anti-TNF, no study has reported a correlation between serum golimumab level and response to drug intensification. The objective of this study was to evaluate the effectiveness and safety of golimumab intensification and to identify the best threshold of serum golimumab before drug intensification predictive of response. Patients and methods: We included all consecutive patients with active UC with loss of response to golimumab in a prospective multicentric cohort study. Patients with loss of response at 50 mg q4 weeks (W) and 100 mg q4W underwent therapeutic intensification at 100 mg q4W and 100 mg q2W, respectively. Effectiveness and safety were assessed between Weeks 2 and 4 (visit 2) and between Weeks 4 and 8 (visit 3) after intensification. Serum level and anti-golimumab antibodies were evaluated at each medical visit (Lisa Tracker, Theradiag France). Results: A total of 47 UC patients (Female, 50%; median age, 39 years (IQR, 27-52)) treated with golimumab for a median of 20.4 weeks (IQR, 10.7-38.3) were included. The median partial Mayo score was 6 (IQR, 5-7), and the median endoscopic Mayo score was 3 (IQR, 2-3). The median golimumab serum level before intensification was 2.23 μg/mL (IQR, 1.02-3.96) and only one patient (2.1%) had anti-drug antibodies. At Visit 2 (Week 2-4), 40% patients experienced clinical response, 10% clinical remission, 33% endoscopic response and 23% endoscopic remission. At Visit 3 (Week 4-8), 44% of patients had clinical response, 22% of patients had clinical remission, 45% of patients had endoscopic response, and 41% of patients had endoscopic remission. The median golimumab levels before intensification do not differ between responders and non-responders (2.13 μg/ml (0.76-2.76) and 3.37 μg/ml (IQR, 1.08-4.67), respectively; p = 0.14) assessed at Visit 3. Golimumab intensification to 100 mg q4W (vs q2W) (OR 1.98, 95% CI [1.06-3.70]; p = 0.032) was significantly associated with clinical remission at Visit 3. Serum drug level at baseline or the presence of antidrug antibodies were not associated with clinical or endoscopic remission/response. Two serious adverse events (one infection and one UC flare) were reported during the 24-week follow-up. Conclusion: In this prospective multicentric study, half of patients recaptured response following golimumab intensification in UC. Therapeutic drug monitoring did not predict response after optimisation of golimumab.
MeSH term(s)	Humans ; Female ; Adult ; Prospective Studies ; Colitis, Ulcerative/drug therapy ; Cohort Studies ; Tumor Necrosis Factor Inhibitors/therapeutic use ; Treatment Outcome ; Remission Induction
Chemical Substances	Tumor Necrosis Factor Inhibitors
Language	English
Publishing date	2023-02-27
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	639012-2
ISSN	1365-2036 ; 0269-2813 ; 0953-0673
ISSN (online)	1365-2036
ISSN	0269-2813 ; 0953-0673
DOI	10.1111/apt.17421
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2206: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Medication Formulation Preference of Mild and Moderate Ulcerative Colitis Patients: a European Survey.

Hébuterne, Xavier / Vavricka, Stephan R / Thorne, Helen C / MacKenzie-Smith, Lara / Laoun, Raphaël / Burisch, Johan

Inflammatory intestinal diseases

2023 Volume 8, Issue 1, Page(s) 41–49

Abstract: Introduction: Patient adherence is a major challenge for the successful management of any chronic disease, and ulcerative colitis (UC) is no exception. Patient adherence is closely related to patient preference of medication and formulation used.: Aim! ...

Abstract	Introduction: Patient adherence is a major challenge for the successful management of any chronic disease, and ulcerative colitis (UC) is no exception. Patient adherence is closely related to patient preference of medication and formulation used. Aim: The aim of this study was to investigate patient and physician perspectives around UC treatment preference. Methods: This study was conducted in France, Germany, Spain, and the UK. Physicians and UK inflammatory bowel disease (IBD) nurses answered an online questionnaire. In addition, adult mild-to-moderate UC patients, treated with oral mesalazine, were invited to answer a 30-min online survey which included a conjoint exercise. Results: 400 patients, 160 physicians, and 20 IBD nurses participated in the survey. 68% of patients were taking tablets and 32% granules. Physicians stated that from their perspective patients are more adherent to tablets than granules (76% vs. 24%), patients tended to have better relief of symptoms with tablets (69% vs. 31%), and patients found tablets to be the most convenient formulation (61% vs. 39%). From the patients' perspective, when questioned which formulation they prefer, 58% answered tablets, 37% granules, and 5% none of these. When patients were asked about some negative attributes of tablets, the highest agreement was for "I would like to take fewer each day" (6.1/10) and "I wish I could take fewer at a time" (5.4/10). Conclusions: The majority of UC patients in this survey prefer the tablet formulation. A high strength tablet overcoming the high pill burden could be a good solution to address patient expectations.
Language	English
Publishing date	2023-05-12
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2817967-5
ISSN	2296-9365 ; 2296-9365
ISSN (online)	2296-9365
ISSN	2296-9365
DOI	10.1159/000530139
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Infliximab is an effective option in patients with ulcerative colitis previously exposed to full subcutaneous anti-TNF agent: Results from a real-world multicenter study.

Hupé, M / Streichenberger, A / Wils, P / Arab, N / Serrero, M / Amiot, A / Bozon, A / Vuitton, L / Fumery, M / Altwegg, R / Nachury, M / Hébuterne, X / Yzet, C / Coban, D / Dodel, M / Bazoge, M / Pereira, B / Buisson, A

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

2024

Abstract: Background: Data on infliximab efficacy in bio-exposed patients with ulcerative colitis (UC) are limited.: Aims: To evaluate infliximab effectiveness and its predictors in UC patients with prior exposure to subcutaneous (SC) anti-TNF agent.: ... ...

Abstract	Background: Data on infliximab efficacy in bio-exposed patients with ulcerative colitis (UC) are limited. Aims: To evaluate infliximab effectiveness and its predictors in UC patients with prior exposure to subcutaneous (SC) anti-TNF agent. Methods: In this multicenter retrospective study (8 centers), we included all consecutive UC patients with prior exposure to subcutaneous anti-TNF, starting infliximab for symptomatic UC, excluding acute severe colitis. Corticosteroid-free clinical remission (CFREM) was assessed at week 14 (W14) and W52 while endoscopic improvement (CFREM + endoscopic Mayo score≤1) was evaluated at W14. Results: Overall, 104 patients were included (pancolitis=54.8%, primary failure to subcutaneous anti-TNF=57.4%, concomitant immunosuppressant=53.8%, median partial Mayo score at baseline=7[5-8]). The rate of CFREM was 33.6% (35/104) at W14 and 40.4% (42/104) at W52. At W14, endoscopic improvement was achieved in 29.8%(31/104). In multivariable analysis, concomitant immunosuppressant was associated with higher rate of CFREM at W14(OR=2.83[1.06-7.54], p = 0.037) and W52(OR=2.68[1.16-6.22];p = 0.021), while primary failure to a previous subcutaneous anti-TNF agent led to lower rate of CFREM at W14 (OR=0.37[0.14-0.98], p = 0.046). After a median follow-up of 20.9 months[11.7-33.7]), 50.0%(52/104) patients had discontinued infliximab. Conclusion: Infliximab is an effective option in UC patients previously exposed to prior subcutaneous anti-TNF agent and should be used with concomitant immunosuppressant.
Language	English
Publishing date	2024-01-27
Publishing country	Netherlands
Document type	Journal Article
ZDB-ID	1459373-7
ISSN	1878-3562 ; 1125-8055
ISSN (online)	1878-3562
ISSN	1125-8055
DOI	10.1016/j.dld.2024.01.181
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1134: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Diarrhées d'origine médicamenteuse.

Hébuterne, Xavier

La Revue du praticien

2008 Volume 58, Issue 11, Page(s) 1213–1216

Abstract: Many drugs have been known to cause diarrhea, although their mechanism of action has not been well described. Determining the etiology of drug-induced diarrhea depends on careful history taking to identify the offending agent. Drug-induced diarrhea may ... ...

Title translation	Drug-induced diarrhea.
Abstract	Many drugs have been known to cause diarrhea, although their mechanism of action has not been well described. Determining the etiology of drug-induced diarrhea depends on careful history taking to identify the offending agent. Drug-induced diarrhea may be classified as watery, inflammatory, fatty diarrhea. Treatment may vary depending on this classification and usually includes withdrawal of the offending drug. However, in some cases, diarrhea may resolve with continued use or through nonspecific agents, such as loperamide.
MeSH term(s)	Diarrhea/chemically induced ; Diarrhea/classification ; Drug-Related Side Effects and Adverse Reactions ; Humans
Language	French
Publishing date	2008-06-15
Publishing country	France
Document type	English Abstract ; Journal Article
ZDB-ID	205365-2
ISSN	2101-017X ; 0035-2640
ISSN (online)	2101-017X
ISSN	0035-2640
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.433: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Induction and Long-term Follow-up With ABX464 for Moderate-to-severe Ulcerative Colitis: Results of Phase IIa Trial.

Vermeire, Séverine / Hébuterne, Xavier / Tilg, Herbert / De Hertogh, Gert / Gineste, Paul / Steens, Jean-Marc

Gastroenterology

2021 Volume 160, Issue 7, Page(s) 2595–2598.e3

MeSH term(s)	Adult ; Aged ; Anti-Inflammatory Agents/administration & dosage ; Colitis, Ulcerative/drug therapy ; Colitis, Ulcerative/pathology ; Double-Blind Method ; Female ; Follow-Up Studies ; Humans ; Induction Chemotherapy/methods ; Male ; Middle Aged ; Quinolines/administration & dosage ; Severity of Illness Index ; Treatment Outcome
Chemical Substances	ABX464 ; Anti-Inflammatory Agents ; Quinolines
Language	English
Publishing date	2021-03-02
Publishing country	United States
Document type	Clinical Trial, Phase II ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
ZDB-ID	80112-4
ISSN	1528-0012 ; 0016-5085
ISSN (online)	1528-0012
ISSN	0016-5085
DOI	10.1053/j.gastro.2021.02.054
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ui V Zs.44: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 572: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito